Let's assume the CF33 is safe but doesn't kill any cancer cell. That way the MAST-trial would come out as ineffective but safe. But if CF33 would at least work just as the CD19 marker and tags solid cancer cells then onCARlytics could still work as we know that CD19 CAR-Ts do a good job, even when currently still complicated and expensive.
They told us about the MAST-trial that they haven't decided yet which cancer to select to progress to the potential rego trial. Could mean no responses at all or all have exceeded expectations. Or just an excuse to let everyone wait to see what onCARlytics does. If onCARlytics works, then nobody would question CF33's abilities of just tagging or actually killing.
IMU Price at posting:
3.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)